Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet
Biophytis announces the publication of an article on the results of its COVA phase 2-3 clinical trial in the treatment of respiratory symptoms in severe forms of COVID-19 in eClinicalMedicine, a medical journal part of the prestigious scientific review The Lancet.
This publication is an endorsement of the strength of Biophytis’ clinical research and the value of our drug candidate Sarconeos (BIO101) in the treatement of severe forms of COVID-19. Therapeutic advances are still needed in this pathology, as more than 230,000 patients will still have died of the virus worldwide in 2023, out of a total of nearly 7 million since the start of the pandemic.